Spine Radiosurgery for Symptomatic Metastatic Neoplasms

PHASE2RecruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

September 9, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2029

Conditions
Metastatic Neoplasm to the SpineMetastatic Neoplasm
Interventions
RADIATION

Conventional external beam radiation therapy dose (EBRT)

Participants will undergo 8 Gray in 1 fraction of EBRT. Questionnaires (brief pain inventory, COST-FACIT, EuroQol EQ-5D) will be administered at baseline, and again at 3,6,9,12 month follow-up.

RADIATION

Spine radiosurgery/stereotactic body radiation therapy standard dose

Participants will undergo 24 Gray in 2 fractions of SBRT. Questionnaires (brief pain inventory, COST-FACIT, EuroQol EQ-5D) will be administered at baseline, and again at 3,6,9,12 month follow-up.

RADIATION

Spine radiosurgery/stereotactic body radiation therapy high dose

Participants will undergo 19 Gray in 1 fraction of SBRT. Questionnaires (brief pain inventory, COST-FACIT, EuroQol EQ-5D) will be administered at baseline, and again at 3,6,9,12 month follow-up.

Trial Locations (2)

21287

ACTIVE_NOT_RECRUITING

Johns Hopkins University Hospitals, Baltimore

73117

RECRUITING

OU Health Stephenson Cancer Center, Oklahoma City

All Listed Sponsors
lead

University of Oklahoma

OTHER

NCT05617716 - Spine Radiosurgery for Symptomatic Metastatic Neoplasms | Biotech Hunter | Biotech Hunter